NEW YORK CITY, Nov. 12, 2025 (WORLD NEWSWIRE)– Pound Pharmaceuticals Inc (” Pound Pharmaceuticals” or the “Business”) (NASDAQ: LBRX) today revealed that it has actually approved to James Rawls, the brand-new Senior Vice President of Regulatory Affairs of Pound Pharmaceuticals, an equity award beyond, however based on the conditions of, the Pound Pharmaceuticals Inc 2025 Equity Reward Strategy. The equity award was approved on November 10, 2025, pursuant to the “temptation grant” exception offered under Nasdaq Listing Guideline 5635( c)( 4) as an incentive product to Mr. Rawls participating in work with pound Pharmaceuticals.
Mr. Rawls got a choice to acquire 90,000 shares of pound Pharmaceuticals’ typical stock. The alternative brings a ten-year term and a workout cost per share equivalent to $14.61, which was the closing cost of pound Pharmaceuticals’ typical stock on the date of grant, and vests over 4 years, with 25% of the shares underlying the alternatives vesting on the very first anniversary of the grant date and an extra 1/48 th of the shares vesting month-to-month afterwards, based on constant service through the appropriate vesting dates.
About LB-102
LB-102 is a Stage 3-ready oral, little particle and a methylated derivative of amisulpride. In early 2025, pound Pharmaceuticals revealed favorable information from a four-week placebo-controlled, double-blinded, Stage 2 trial in clients with intense schizophrenia. The Stage 2 trial showed statistically considerable advantage versus placebo at all dosages studied, a possibly class prominent security profile amongst D2 villains and partial agonists, and favorable impacts on unfavorable signs and cognition. LB-102 is advancing into a Stage 3 scientific trial for intense schizophrenia and a Stage 2 scientific trial for bipolar anxiety. Extra growth chances for LB-102 might consist of significant depressive condition (MDD), primarily unfavorable signs of schizophrenia, Alzheimer’s illness psychosis and agitation, in addition to bipolar mania and cognitive disability connected with schizophrenia.
About Pound Pharmaceuticals
Pound Pharmaceuticals is a clinical-stage biopharmaceutical business establishing unique treatments for the treatment of schizophrenia, bipolar anxiety, and other neuropsychiatric illness. The Business is developing a pipeline that leverages the broad restorative capacity of its lead item prospect, LB-102, which the Business thinks has the prospective to be the very first benzamide antipsychotic drug authorized for neuropsychiatric conditions in the United States. LB-102, if authorized, has the prospective to end up being an essential of psychiatric practice by using a possibly appealing option to branded and generic therapies for the treatment of schizophrenia, bipolar anxiety, and other neuropsychiatric illness.
Contacts
Media:
Michael Tattory
LifeSci Communications
Mtattory@lifescicomms.com
Financier Relations:
Joyce Allaire
LifeSci Advisors
JAllaire@LifeSciAdvisors.com